Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.

摘要: Esmolol is a new ultra short-acting (half-life [t1/2] beta 9 min) 1-adrenergic-receptor antagonist reported to have no intrinsic sympathomimetic activity. The safety and efficacy of esmolol in lowering the ventricular rate rate-pressure product patients with acute myocardial infarction (n = 5), postmyocardial angina 10), or unstable 4), without cardiogenic shock were studied. After 30 min observation period, was titrated maximum dose 300 micrograms/kg/min infused for up 420 min. fell from 92 +/- 11 (mean SD) 77 13 beats/min (p less than .01) systolic arterial pressure decreased 120 97 mm Hg during initial titration period. There significant change maintenance phase, both returned rapidly toward baseline values within termination infusion. cardiac index 2.8 0.6 2.2 liters/min/m2 same also level after pulmonary capillary wedge pressure, respiratory rate, PR interval. Five required infusion because hypotension all recovered uneventfully stopping esmolol. One patient brief dopamine restore hemodynamic stability.(ABSTRACT TRUNCATED AT 250 WORDS)